Longevity and Reproductive Aging Reproductive Aging

Can ovarian aging be delayed by pharmacological strategies?

Zhang J, Chen Q, Du D, Wu T, Wen J, Wu M, Zhang Y, Yan W, Zhou S, Li Y, Jin Y, Luo A, Wang S

Published January 23, 2019 Aging
DOI 10.18632/aging.101784 PMID 30674710 PMC PMC6366956

RRM Academy Synopsis

Several drugs and supplements delayed ovarian aging in animal studies

Many drugs and supplements delayed ovarian aging in animal and lab studies. This review summarizes that published research.

Key Findings

  • Antioxidants reviewed include vitamins C and E, N-acetyl-L-cysteine, curcumin, coenzyme Q10, proanthocyanidin and quercetin. Much of the cited evidence comes from mice, rats and hens.
  • Caloric restriction delayed ovarian aging in rodents. Metformin, 2-deoxy-glucose, tamoxifen and rapamycin were studied as mimics. One cited study found metformin had no significant effect on ovarian reserve.
  • Melatonin delayed ovarian aging in mice and rats. The one clinical study described gave melatonin for six months to perimenopausal and postmenopausal women aged 42 to 62.
  • Cited studies in patients with diminished ovarian reserve report DHEA supplementation improved ovarian markers such as AMH and antral follicle count. The authors add that long-term DHEA treatment may affect follicle development.
  • The authors report no drugs yet target microRNAs to delay ovarian aging, and few target autophagy. Many traditional Chinese medicine results cited come from rat and mouse experiments.

Interpretation

This review looked at published studies on drugs and supplements that may delay ovarian aging. The authors list several kinds of candidates, such as antioxidants, melatonin and DHEA. Most of the cited work was done in animals or cells. DHEA and melatonin showed effects in the human studies the authors cite. The findings support larger human trials of these candidates.

RRM Context

Restorative reproductive medicine asks why a couple's fertility has changed. Age is one answer among several. Cycle charting and a check of both partners can show if ovulation, hormones or male factors also play a role. AMH shows follicle supply, and RRM clinicians read it along with the cycle.

Abstract

Aging has been regarded as a treatable condition, and delaying aging could prevent some diseases. Ovarian aging, a special type of organ senescence, is the earliest-aging organ, as ovaries exhibit an accelerated rate of aging with characteristics of gradual declines in ovarian follicle quantity and quality since birth, compared to other organs. Ovarian aging is considered as the pacemaker of female body aging, which drives the aging of multiple organs of the body. Hence, anti-ovarian aging has become a research topic broadly interesting to both biomedical scientists and pharmaceutical industry. A marked progress has been made in exploration of possible anti-ovarian agents or approaches, such as calorie restriction mimetics, antioxidants, autophagy inducers etc., over the past years. This review is attempted to discuss recent advances in the area of anti-ovarian aging pharmacology and to offer new insights into our better understanding of molecular mechanisms underlying ovarian aging, which might be informative for future prevention and treatment of ovarian aging and its related diseases.

Topics

By this author

Related research

Longevity and Reproductive Aging › Reproductive Aging › Ovarian Aging · Therapeutics › Supplements and Botanicals › Antioxidant Supplements
Jinjin Zhang, Qian Chen, Dingfu Du, Tong Wu, Jingyi Wen, Meng Wu, Yan Zhang, Wei Yan, Su Zhou, Yan Li, Yan Jin, Aiyue Luo, Shixuan Wang
J Zhang, Q Chen, D Du, T Wu, J Wen, M Wu, Y Zhang, W Yan, S Zhou, Y Li, Y Jin, A Luo, S Wang
PMID 30674710 30674710 DOI 10.18632/aging.101784 10.18632/aging.101784 Zhang et al. 2019, Zhang 2019